Challenges in targeting residual risk in diabetic patients, post ACS

Back

ESC Premium Access

Challenges in targeting residual risk in diabetic patients, post ACS

Session: Epigenetics: a new pathway to tackle residual risk?

Topic: Clinical

Speaker: Professor P. Libby (Boston, US)

Organised by PACE-CME, supported with an educational grant provided by Resverlogix

Event: ESC Congress 2019

Congress Presentation

About the speaker

Professor Peter Libby

Brigham and Women's Hospital, Boston (United States of America)

35 presentations

6 followers

4 more presentations in this session

Introduction

Speaker: Professor U. Landmesser (Berlin, DE)

Access

Slides

Video

BET inhibition, an epigenetic pathway: how could BET inhibition modulate atherothrombotic risk

Speaker: Professor J. Jukema (Leiden, NL)

Access

Slides

Video

Clinical update on BET inhibition: the patient profile that may benefit from BET inhibition?

Speaker: Professor K. Ray (London, GB)

Access

Slides

Video

Discussion

Speaker: Professor U. Landmesser (Berlin, DE) Professor K. Ray (London, GB)

Access

Slides

Video

Access the full session

Epigenetics: a new pathway to tackle residual risk?

Speakers: Professor P. Libby, Professor U. Landmesser, Professor J. Jukema, Professor K. Ray, Professor U. Landmesser...

Access

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

Challenges in targeting residual risk in diabetic patients, post ACS

About the speaker

Professor Peter Libby

4 more presentations in this session

Introduction

BET inhibition, an epigenetic pathway: how could BET inhibition modulate atherothrombotic risk

Clinical update on BET inhibition: the patient profile that may benefit from BET inhibition?

Discussion

Access the full session

Epigenetics: a new pathway to tackle residual risk?

About the event

ESC Congress 2019

ESC 365 is supported by